Timolol tablet contraindications: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Timolol}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TIMOLOL MALEATE TABLET [MYLAN PHARMACEUTICALS INC.] | url = ht...") |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Contraindications== | ||
Timolol maleate is contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see WARNINGS); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (seeWARNINGS); cardiogenic shock; hypersensitivity to this product.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TIMOLOL MALEATE TABLET [MYLAN PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57c62928-63d8-4505-9b9e-c085a3a12c95#nlm34089-3 | publisher = | date = | accessdate = }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TIMOLOL MALEATE TABLET [MYLAN PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=57c62928-63d8-4505-9b9e-c085a3a12c95#nlm34089-3 | publisher = | date = | accessdate = }}</ref> | |||
==References== | ==References== | ||
Revision as of 00:57, 9 February 2014
| Timolol |
|---|
| TIMOLOL MALEATE® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Timolol |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Contraindications
Timolol maleate is contraindicated in patients with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see WARNINGS); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (seeWARNINGS); cardiogenic shock; hypersensitivity to this product.[1]
References
Adapted from the FDA Package Insert.